Literature DB >> 6125166

Beta-adrenoceptor blockade and atrio-ventricular conduction in dogs. Role of intrinsic sympathomimetic activity.

J F Giudicelli, F Lhoste.   

Abstract

1 Atrio-ventricular conduction and its modifications induced by six beta-adrenoceptor blocking agents and isoprenaline have been investigated in the anaesthetized dog using the extrastimulus technique and measuring atrial (AERP), nodal (NERP), global (GERP) effective refractory periods as well as global functional refractory period (GFRP). 2 When beta-adrenoceptor blockade was produced by (+/-)-propranolol (beta 1 + beta 2-adrenoceptor blockade) which is devoid of intrinsic sympathomimetic activity (ISA) but has membrane stabilizing effects (MSE), sotalol (beta 1 + beta 2-adrenoceptor blockade, no ISA, no MSE) and atenolol (beta 1-adrenoceptor blockade, no ISA, no MSE), all parameters were significantly increased. When beta-adrenoceptor blockade was achieved with pindolol (beta 1 + beta 2-adrenoceptor blockade) and practolol (beta 1-adrenoceptor blockade) which have ISA but no MSE, all parameters remained unchanged, as was also the case with (+)-propranolol, which has MSE but neither ISA nor beta-adrenolytic properties. 3 Isoprenaline at high doses significantly reduced the refractory periods but when infusion was stopped, marked but reversible conduction depression was observed. 4 It thus appears that beta-adrenoceptor blockade but not MSE is responsible for the onset of atrial and AV-conduction impairment and that ISA affords protection against this impairment.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6125166      PMCID: PMC1402132          DOI: 10.1111/j.1365-2125.1982.tb01906.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  Physiologic evidence for a dual A-V transmission system.

Authors:  G K MOE; J B PRESTON; H BURLINGTON
Journal:  Circ Res       Date:  1956-07       Impact factor: 17.367

Review 2.  Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 2. Physiologic and metabolic effects.

Authors:  W Frishman; R Silverman
Journal:  Am Heart J       Date:  1979-06       Impact factor: 4.749

3.  The negative inotropic effect of adrenergic betareceptor blocking drugs on human heart muscle.

Authors:  W G Nayler; D Chipperfield; T E Lowe
Journal:  Cardiovasc Res       Date:  1969-01       Impact factor: 10.787

4.  Myocardial and local anesthetic actions of beta-adrenergic receptor blocking drugs: relationship to physicochemical properties.

Authors:  J V Levy
Journal:  Eur J Pharmacol       Date:  1968-02       Impact factor: 4.432

5.  Selective blockade of adrenoceptive beta receptors in the heart.

Authors:  D Dunlop; R G Shanks
Journal:  Br J Pharmacol Chemother       Date:  1968-01

6.  Supernormality in Bachmann's bundle. An in vitro and in vivo study in the dog.

Authors:  R W Childers; J Merideth; G K Moe
Journal:  Circ Res       Date:  1968-03       Impact factor: 17.367

7.  Significance of His and left bundle recordings from the left heart in man.

Authors:  O S Narula; R P Javier; P Samet; L C Maramba
Journal:  Circulation       Date:  1970-09       Impact factor: 29.690

8.  Studies on dl-4-(2-hydroxy-3-isopropylaminopropoxy)-indole A/Giudicelli JF, Schmitt H, Boissier JR: Studies on dl-4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB 46), a new potent beta adrenergic blocking drug.

Authors:  J F Giudicelli; H Schmitt; J R Boissier
Journal:  J Pharmacol Exp Ther       Date:  1969-07       Impact factor: 4.030

9.  Beta-adrenergic blockade and atrio--ventricular conduction impairment.

Authors:  J F Giudicelli; F Lhoste; J R Boissier
Journal:  Eur J Pharmacol       Date:  1975-04       Impact factor: 4.432

10.  Electrophysiological effects of isoproterenol on Purkinje fibers of the heart.

Authors:  D G Kassebaum; A R Van Dyke
Journal:  Circ Res       Date:  1966-11       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.